The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Abdel-Fatah, Tarek M A; Rees, Robert C; Pockley, A Graham; Moseley, Paul; Ball, Graham R; Chan, Stephen Y T; Ellis, Ian O; Miles, Amanda K

Abdel-Fatah, Tarek M A; Rees, Robert C; Pockley, A Graham; Moseley, Paul; Ball, Graham R; Chan, Stephen Y T; Ellis, Ian O; Miles, Amanda K.

Afiliação

Abdel-Fatah TMA; Department of Clinical Oncology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, UK.
Rees RC; The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, NG11 8NS, UK.
Pockley AG; The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, NG11 8NS, UK.
Moseley P; Department of Clinical Oncology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, UK.
Ball GR; The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, NG11 8NS, UK.
Chan SYT; Department of Clinical Oncology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, UK.
Ellis IO; Department of Histopathology, Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, NG5 1PB, UK.
Miles AK; The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, NG11 8NS, UK.

Oncotarget ; 8(68): 112245-112257, 2017 Dec 22.

Article em En | MEDLINE | ID: mdl-29348822

Palavras-chave

ER-negative/HER2-positive breast cancer; PRPF38B; cancer antigen; poor prognosis; trastuzumab therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google